---

Male Reproductive Disorders: A Detailed Clinical Review

---

1. Male Hypogonadism (Androgen Deficiency)

Definition and Epidemiology

• Klinefelter syndrome (the most common genetic cause): ~5 per 10,000 men
• Iatrogenic causes (chemotherapy, testicular/pituitary radiotherapy) are the most common etiologies aside from age and obesity
• Obesity and aging together produce mixed testicular + hypothalamic-pituitary dysfunction

Classification

Causes

• Congenital: Klinefelter syndrome (47,XXY and variants), testosterone biosynthetic enzyme defects, 5α-reductase deficiency, androgen resistance syndrome, myotonic dystrophy
• Developmental: Cryptorchidism
• Acquired: Orchitis (mumps, HIV), granulomatous disease (TB, leprosy), infiltrative disease (hemochromatosis, amyloidosis), trauma/torsion, irradiation, toxins (alcohol, heavy metals, DDT, insecticides)
• Drugs: Cytotoxic agents (alkylating agents), ketoconazole, abiraterone, cimetidine, flutamide, cyproterone, spironolactone
• Autoimmune testicular failure
• Systemic disease: Cirrhosis, chronic renal failure, sickle cell disease

• Congenital/idiopathic: Isolated GnRH deficiency - Kallmann syndrome (with anosmia, 80% of cases) or without anosmia; Prader-Willi syndrome; Laurence-Moon-Biedl syndrome
• Acquired: Traumatic brain injury, pituitary/cranial surgery or irradiation, pituitary adenomas (prolactinoma - most common pituitary tumor in men, usually a macroadenoma >1 cm at presentation), other pituitary tumors, autoimmune hypophysitis (including checkpoint inhibitor-induced), hemochromatosis, alcohol abuse disorder, type 2 diabetes, HIV

Pathophysiology

• Primary: Testicular failure → low testosterone → loss of negative feedback → ↑ LH and FSH
• Secondary: Hypothalamic or pituitary failure → ↓ GnRH or gonadotropins → low LH/FSH → low testosterone
• Obesity → lower SHBG + decreased testosterone secretion → low total and free testosterone
• Androgen resistance states (androgen receptor defects, 5α-reductase deficiency) - testosterone is normal or elevated, but action is impaired

Clinical Manifestations

Diagnosis

1. Morning serum total testosterone (8-10 AM; normal 264-916 ng/dL in European/American men aged 19-39 yrs) - must be confirmed on at least 2 occasions
2. LH and FSH: ↑ = primary; normal to low = secondary
3. Prolactin: Measure if LH + testosterone are both low (to rule out prolactinoma)
4. SHBG: Elevated in hyperthyroidism, liver disease, estrogen excess; low in hypothyroidism, obesity, PCOS, acromegaly
5. Semen analysis: Assesses spermatogenesis
6. MRI pituitary: If secondary hypogonadism suspected or prolactin elevated
7. Bone mineral density (BMD)
8. Genetic studies (karyotype for Klinefelter; Y microdeletion for azoospermia)

• Testicular volume <15 mL (orchidometer)
• Small, firm testes (Klinefelter)
• Anosmia (Kallmann syndrome)
• Gynecomastia, decreased facial/body hair, reduced muscle mass, micropenis

Treatment: Testosterone Replacement Therapy (TRT)

Note: Modified 17α-alkylated androgens (e.g., methyltestosterone) are hepatotoxic and should not be used for TRT.

---

2. Male Infertility

Definition and Epidemiology

• Male factor alone: 25-30%
• Female factor alone: 30-35%
• Combined: 25-30%
• Unexplained: ~20%

Causes (Table 35-14 - Common Diagnoses)

Pathobiology

• Testicular disorders = most frequent identifiable cause
• Epididymis = main site for sperm maturation; lumicrine factor disruptions may explain many cases
• Genetic causes (now diagnosable in up to 50% with exome/whole-genome sequencing):
  • Chromosomal disorders and translocations
  • Y chromosome microdeletions (up to 25% of infertile men; Yq11 region = azoospermia factor, AZF)
    • AZFa and AZFb mutations → azoospermia
    • AZFc mutations → oligozoospermia
  • TEX11 gene mutations, STAG3, DMRT1 → meiotic arrest/azoospermia
  • Ciliary dyskinesia, flagellar abnormalities, sperm head defects

Workup

Diagnostic Algorithm

• ↓T, ↑FSH, ↑LH → Primary hypogonadism → androgen therapy
• Normal T, ↑FSH, normal LH → Germinal epithelium failure → retrieve ejaculate/testicular sperm for ICSI
• ↓T, ↓FSH, ↓LH → Hypogonadotropic hypogonadism → gonadotropins/GnRH/testosterone
• ↑T, normal FSH, ↑LH → Partial androgen resistance

Management

1. Treat underlying infection with antibiotics (if genital tract infection present)
2. Varicocelectomy (for varicocele-associated infertility)
3. Counseling about lifestyle and environmental factors (heat exposure, toxins)
4. Gonadotropin therapy (hCG + FSH) for hypogonadotropic hypogonadism - highly effective
5. ART/ICSI (intracytoplasmic sperm injection) for severe oligospermia or azoospermia
6. Microsurgical testicular sperm extraction (micro-TESE) + ICSI for non-obstructive azoospermia - even successful in Klinefelter syndrome
7. Empirical medical treatments (clomiphene citrate, aromatase inhibitors, recombinant FSH) - not generally recommended due to limited evidence, though high-dose FSH (700-1050 IU/week) can increase sperm concentration and motility
8. Obstructive azoospermia (absent vas deferens, vasectomy reversal) - surgical reconstruction or sperm retrieval for ICSI

---

3. Erectile Dysfunction (ED)

Definition and Epidemiology

• 10-15% of all adult American men
• 52% of men aged 40-70 years have some degree of ED (Massachusetts Male Aging Study)
• Higher prevalence in type 2 diabetes mellitus and after radical prostatectomy
• Strongly associated with lower urinary tract symptoms/BPH and cardiovascular disease (shared risk factors)

Pathobiology and Causes

ED shares cardiovascular risk factors (smoking, obesity, metabolic syndrome, hyperlipidemia, type 2 DM) and mild ED should prompt cardiovascular assessment.

Diagnosis

• Detailed medical and sexual history (including partner when possible)
• Physical exam: Genitourinary, cardiovascular, endocrine (gynecomastia), neurologic, prostate exam
• Laboratory: Morning serum testosterone, PSA (if indicated), fasting glucose/HbA1c, cholesterol
• Specific diagnostic tests (penile Doppler, nocturnal penile tumescence) are rarely required in routine practice

• Antihypertensives (β-blockers, thiazides, clonidine)
• Antidepressants (SSRIs, TCAs)
• Antipsychotics
• Antiandrogens (finasteride, spironolactone, ketoconazole)
• Opioids, alcohol, recreational drugs

Treatment

• Treat reversible causes (correct hypogonadism, stop offending drugs, control diabetes, manage cardiovascular risk)
• Lifestyle modification: weight loss, exercise, smoking cessation, alcohol reduction
• Education and counseling to patient and partner

• Sildenafil, vardenafil, tadalafil - all effective in ~60% of men
• Mechanism: inhibit PDE5 → ↑ cGMP → sustained NO-mediated cavernous smooth muscle relaxation
• Absolute contraindication: Nitrates (risk of severe hypotension)
• Also caution with α-blockers (orthostatic hypotension)
• Less effective in: diabetes, post-radical prostatectomy, spinal cord injuries (but may still help)

• Vacuum erection devices
• Intraurethral alprostadil (prostaglandin E2 suppository, 125-1000 μg) - effective in 30-66%
• Psychosexual counseling

• Alprostadil (prostaglandin E1) alone or combined with papaverine and phentolamine ("trimix")
• Injected with 27-30 gauge needle; side effects: pain, cavernosal fibrosis
• Botulinum neurotoxin (single injection) effective in ~40-50% of PDE5i-refractory patients

• L-arginine + low-intensity shockwave therapy + PDE5i combination
• Dulaglutide (GLP-1 agonist) shown to reduce moderate-severe ED in men with type 2 DM and cardiovascular disease

• Semi-rigid (malleable) or inflatable devices
• For men who prefer a permanent solution or are refractory to other treatments
• Long-term patient and partner satisfaction is high with proper selection
• Complications: corporal perforation, urethral injury, infection, hematoma; mechanical failure in 10-20% of inflatable devices by 10 years

---

Summary: Key Distinguishing Features

---

---

Sleep Apnea: Detailed Clinical Review

---

1. Definitions and Classification

• Apnea: Cessation of breathing ≥10 seconds
• Hypopnea: Reduction in airflow (not complete cessation) associated with ≥3-4% O₂ desaturation and/or microarousal
• RERA (respiratory effort-related arousal): Mild upper airway narrowing with inspiratory flow flattening, not meeting hypopnea criteria, but terminating with microarousal
• AHI (apnea-hypopnea index): Number of apneas + hypopneas per hour of sleep

OSA Severity Classification (AASM)

---

2. Epidemiology

• OSA is highly prevalent - among the most common sleep disorders seen by pulmonologists
• Affects 300-500 apneic episodes per night in severe cases, with O₂ saturation dropping to ≤60%
• More common in men than women, but substantially under-recognized in women
• Prevalence increases with age, obesity, and male sex
• Women with untreated OSA have 3.5x greater risk of dying from cardiovascular disease (CVD) - normalized with appropriate CPAP treatment (Braunwald)

---

3. Pathogenesis

Upper Airway Collapse - The Core Mechanism

1. Reduced upper airway dimensions - retrognathic mandible, increased tongue/lateral wall volume, increased airway length
2. High airway collapsibility (Pcrit) - measured as critical closing pressure:
   • Normal: Pcrit < -10 cm H₂O
   • Nonapneic snoring: Pcrit -10 to -5 cm H₂O
   • Obstructive hypopnea: Pcrit -5 to 0 cm H₂O
   • Obstructive apnea: Pcrit > 0 cm H₂O
3. Impaired neuromuscular compensation - reduced genioglossus and other dilator muscle responses during sleep
4. Fluid shift - rostral redistribution of fluid from legs to neck during recumbency (especially in heart failure, venous insufficiency)
5. Reduced lung volume in recumbency - less caudal tracheal traction → reduced upper airway patency
6. Airway inflammation and edema - from chronic intermittent snoring trauma and nocturnal fluid accumulation

Sequence During an Apneic Episode

1. Upper airway collapses → airflow ceases
2. O₂ falls, CO₂ rises progressively
3. Increasing and increasingly forceful ventilatory effort (visible on PSG as paradoxical thoracoabdominal movement)
4. Critical hypoxemia/hypercapnia threshold triggers arousal
5. Arousal restores dilator muscle tone → airway reopens → loud snort/gasp
6. Cycle repeats - 300-500 times nightly in severe cases
7. Blood pressure surges at end of each apnea - can reach 240/130 mmHg transiently

Central Sleep Apnea Mechanism

• Transient abolition of CNS drive to respiratory muscles
• Causes: brainstem damage (stroke), heart failure (Cheyne-Stokes), opioids, high-loop gain respiratory instability
• Patients are extremely sensitive to sedatives/narcotics
• Treatment: Respiratory stimulants (limited), CPAP, BPAP, or ASV (adaptive servo-ventilation)

---

4. Risk Factors / Predisposing Factors

---

5. Clinical Presentation

Nocturnal Symptoms

• Loud snoring (universal in OSA; preceded by labored breathing)
• Witnessed apneas (partner reports breathing pauses)
• Choking or gasping arousals
• Nocturia
• Restless, fragmented sleep
• Diaphoresis

Daytime Symptoms

• Excessive daytime sleepiness (hallmark - measured with Epworth Sleepiness Scale)
• Morning headaches (CO₂ retention)
• Cognitive impairment - poor memory, concentration, executive function
• Mood disturbance (depression, irritability)
• Fatigue unrelieved by sleep

Epworth Sleepiness Scale (ESS)

---

6. Polysomnography (PSG) - The Diagnostic Gold Standard

Diagnostic Testing Options

• Snoring, Tiredness, Observed apneas, Pressure (hypertension), BMI >35, Age >50, Neck >40 cm, Gender (male)

---

7. Consequences and Complications

Neurocognitive

• Excessive daytime sleepiness → increased motor vehicle accidents (2-7x baseline risk)
• Impaired attention, memory, executive function
• Increased depression and anxiety

Cardiovascular (Major)

• Systemic hypertension - OSA is the most common secondary cause of resistant hypertension
• Coronary artery disease - 2-3x increased risk
• Stroke - independent risk factor
• Atrial fibrillation - increased risk; OSA worsens AF recurrence after cardioversion
• Pulmonary hypertension (in severe/untreated OSA)
• Heart failure - both cause and consequence; CSA with Cheyne-Stokes breathing is common in HF
• Transient BP surges to 240/130 mmHg during apneic episodes → endothelial damage
• Increased sympathetic nervous system activity, oxidative stress, systemic inflammation

Metabolic

• Insulin resistance and type 2 diabetes (independent association)
• Obesity (bidirectional - worsens OSA, OSA worsens metabolic dysregulation)
• Non-alcoholic fatty liver disease

Other

• Nocturia (increased ANP release due to intrathoracic pressure swings)
• Erectile dysfunction (hypoxia + sympathetic activation)
• Gastroesophageal reflux (negative intrathoracic pressure)
• Pulmonary hypertension (right heart strain in severe untreated OSA)

---

8. Diagnosis - Approach

1. History and physical exam - sleep history, BMI, neck circumference, oropharyngeal exam (Mallampati score, tonsillar size, palate), nasal patency
2. Screening questionnaire - STOP-BANG or Epworth Sleepiness Scale
3. Objective sleep testing before starting any therapy (to guide treatment selection)
   • Home sleep apnea test (HSAT) for uncomplicated suspected OSA
   • In-lab PSG for complex presentations (suspicion of CSA, hypoventilation, parasomnias, heart failure, neuromuscular disease, prior inconclusive HSAT)
4. Laboratory tests: TSH (hypothyroidism), fasting glucose, consider morning cortisol if central hypoventilation

---

9. Treatment

A. Behavioral and Lifestyle Modifications

• Weight loss - strongly recommended for all overweight/obese OSA patients; can resolve mild-moderate OSA with substantial loss
• Positional therapy - for positional OSA (AHI worse in supine): non-supine sleeping devices, head-of-bed elevation
• Alcohol and sedative avoidance - especially within 4 hours of sleep
• Sleep hygiene - regular sleep schedule, adequate total sleep time

B. Positive Airway Pressure (PAP) Therapy - First-Line for Moderate-Severe OSA

C. Oral Appliance Therapy (Mandibular Advancement Device)

• Repositions the mandible and tongue anteriorly, increasing oropharyngeal space
• Appropriate for mild-moderate OSA, or as alternative/complement to PAP
• Takes 3 months to complete evaluation + fabrication + adjustments
• Less effective than CPAP but better tolerated by some patients
• Requires intact dentition

D. Surgical Options

E. Pharmacologic Therapy

• Solriamfetol and modafinil - approved for residual excessive daytime sleepiness despite adequate PAP use
• GLP-1 receptor agonists (semaglutide, tirzepatide) - substantial weight loss from these agents improves OSA severity; emerging data shows direct benefit
• Acetazolamide - useful for central apneas at high altitude; reduces loop gain
• Oxygen supplementation - may be used adjunctively in central sleep apnea or as bridge therapy

F. Special Situations

• CPAP is beneficial
• ASV is contraindicated in HFrEF (EF <45%) - SERVE-HF trial showed increased mortality

---

10. Central Sleep Apnea - Special Considerations

---

11. Summary: Key Clinical Pearls

• OSA is defined by AHI ≥5 with symptoms, or AHI ≥15 regardless of symptoms
• CPAP is the most effective treatment - pneumatically splints the airway open; adherence (≥4 hrs/night on ≥70% of nights) is the key measure
• Weight loss is the only potentially curative intervention for obesity-related OSA
• OSA is the most common secondary cause of resistant hypertension - always screen for it
• Untreated OSA dramatically increases cardiovascular risk - 3.5x CVD mortality in women, increased rates of MI, stroke, AF
• Never use ASV in HFrEF (EF <45%) with central/mixed sleep apnea
• Mild-moderate OSA can be managed with oral appliance therapy as an effective PAP alternative
• Hypoglossal nerve stimulation (Inspire) is an effective surgical option for selected patients who cannot tolerate PAP
• Always check for hypothyroidism and acromegaly in OSA patients resistant to standard therapy

---